EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy

Kirti Arora, Lara Soueid, Louis Williams, Jahanvi Grover iD, Diana Basali, Jack Khouri iD, Yuvraj Kaushal, Sandra Mazzoni iD, Rockey Dahiya iD, Beth Faiman iD, Jason Valent iD, Faiz Anwer und 1 weitere

Cancers · 07.05.2026 · 18 (10) · 1505

DOI: 10.3390/cancers18101505 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.05.2026. Verfasst von Kirti Arora und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44106, USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by a heterogeneous risk of progression to overt multiple myeloma (MM). Historically managed with active surveillance, advances in risk stratification and the development of novel therapeutics have renewed debate regarding early intervention, particularly in patients with high-risk disease. We conducted a narrative review of clinical trials and observational studies evaluating early treatment versus observation in SMM. Outcomes assessed included progression-free survival (PFS), time to progression (TTP), overall survival (OS), treatment-related toxicity, and quality-of-life measures, alongside evolving diagnostic criteria and risk-stratification models that influence therapeutic decision-making. Early randomized trials using conventional cytotoxic therapy did not demonstrate a survival advantage and supported observation as the standard management approach. However, contemporary studies using novel agents have demonstrated improved disease control in selected high-risk populations. The QuiRedex and ECOG-E3A06 trials showed significant reductions in progression risk with lenalidomide-based therapy, and long-term follow-up suggests a potential overall survival benefit in Qui-Redex. The phase III AQUILA trial further demonstrated delayed progression with daratumumab in high-risk SMM using updated diagnostic criteria. Phase II studies evaluating combination regimens, including KRd-based and daratumumab-containing approaches, have reported high response rates and MRD negativity, although survival data remain immature. Importantly, many benefits reflect delayed biochemical or imaging-defined progression rather than prevention of symptomatic end-organ damage. Current evidence supports selective early intervention in carefully defined high-risk SMM populations; however, uncertainties remain regarding long-term survival benefit, optimal treatment duration, quality-of-life impact, and clonal evolution. Active surveillance with modern monitoring remains appropriate for many patients.

Schlagwörter

Stichwörter der Autor:innen

daratumumabearly interventionlenalidomidemeasurable residual diseaseprogression-free survivalrisk stratificationsmoldering multiple myelomasurveillance

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44106, USA.

ORCID-Profile: Jahanvi Grover, Jack Khouri, Sandra Mazzoni, Rockey Dahiya, Beth Faiman, Jason Valent, Shahzad Raza

Zitieren

APA

Arora, K., Soueid, L., Williams, L., Grover, J., Basali, D., Khouri, J., Kaushal, Y., Mazzoni, S., Dahiya, R., Faiman, B., Valent, J., Anwer, F., & Raza, S. (2026). Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy. Cancers, 18(10), 1505. https://doi.org/10.3390/cancers18101505

Vancouver

Arora K, Soueid L, Williams L, Grover J, Basali D, Khouri J, et al. Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy. Cancers. 2026;18(10):1505. doi:10.3390/cancers18101505

BibTeX
@article{Arora2026,
  author = {Arora, Kirti and Soueid, Lara and Williams, Louis and Grover, Jahanvi and Basali, Diana and Khouri, Jack and Kaushal, Yuvraj and Mazzoni, Sandra and Dahiya, Rockey and Faiman, Beth and Valent, Jason and Anwer, Faiz and Raza, Shahzad},
  title = {Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1505},
  doi = {10.3390/cancers18101505}
}
Kostenlos starten →